Thomas Joseph Schuetz MD

Physician

62 Lexington StFramingham, MA 01702
Phone+1 774-279-0876
Fax+1 508-872-4621

Join Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting!
Read the latest clinical news, personalized to your specialty.

Join Doximity Already have an account?

Summary

Dr. Thomas Schuetz, MD is an oncologist in Framingham, Massachusetts.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
Harvard Medical SchoolClass of 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Publications & Presentations

PubMed

1 citations
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity.
Diana I Albu, Benjamin J Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben
Oncoimmunology. 2024-01-01
43 citations
Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development.
Weon-Kyoo You, Thomas J Schuetz, Sang Hoon Lee
Molecular Cancer Therapeutics. 2023-01-03
731 citations
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff, T. Schuetz, Brent A. Blumenstein, L. Michael Glode, David L. Bilhartz
Journal of Clinical Oncology. 2010-03-01

Press Mentions

Compass Therapeutics Announces That the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Will Be Presented at the ASCO GI Cancers Symposium on January 20, 2023January 19th, 2023
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor a (VEGF-A)January 20th, 2022
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 8th, 2021